[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100245330":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":38,"locations":45,"responsibleParty":83,"collaborators":29,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":29,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":70,"whyStopped":29,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"blood pressure lowering algorithm","EXPERIMENTAL","enhanced strategy aiming to reduce systolic blood pressure to \\\u003C135 mmHg",[13],"Other: blood pressure lowering algorithm",{"label":15,"type":16,"description":17,"interventionNames":18},"usual strategy","ACTIVE_COMPARATOR","usual strategy based on the usual care of routine care",[19],"Other: usual strategy",[21,26],{"type":6,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"The treatments used in the \"enhanced strategy\" arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study.",[9],[25],"enhanced strategy",{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.",[15],null,[31,35],{"name":32,"affiliation":33,"role":34},"Christophe TZOURIO, MD, PhD","Inserm U897 - Bordeaux University","STUDY_DIRECTOR",{"name":36,"affiliation":5,"role":37},"Olivier HANON, MD, PhD","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":29,"email":42},"CONTACT","33 1 44 08 35 02","olivier.hanon@brc.aphp.fr",{"name":32,"role":40,"phone":29,"phoneExt":29,"email":44},"christophe.tzourio@u-bordeaux.fr",[46,68],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Memory for Research and Resources Center \u002F Neuroscience pole","NOT_YET_RECRUITING","Bordeaux","Pellegrin Hospital Group","33076","France","FR",{"type":55,"coordinates":56},"Point",[57,58],-0.58046,44.84124,{"lat":58,"lon":57},[61,64],{"name":62,"role":40,"phone":63,"phoneExt":29,"email":44},"Christophe Tzourio, MD, PhD","+33 (0)5 57 57 16 59",{"name":65,"role":40,"phone":66,"phoneExt":29,"email":67},"Stéphanie DEBETTE, MD, PhD","Tel: +33 (0) 5 57 57 16 59","stephanie.debette@isped.u-bordeaux2.fr",{"facility":69,"status":70,"city":71,"state":29,"zip":72,"country":52,"countryCode":53,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Memory Resources Centre and South of Ile de France Search - Broca Hospital","RECRUITING","Paris","75013",{"type":55,"coordinates":74},[75,76],2.3488,48.85341,{"lat":76,"lon":75},[79,80,82],{"name":36,"role":40,"phone":41,"phoneExt":29,"email":42},{"name":65,"role":40,"phone":81,"phoneExt":29,"email":67},"+33 (0) 5 57 57 16 59",{"name":36,"role":37,"phone":29,"phoneExt":29,"email":29},{"type":84,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100245330","phase-4-blood-pressure-reduction-to-limit-the-evolution-of-vascular-brain-lesions-in-elderly-individuals-100245330",false,"NCT02472028","Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals","LEukoaraiosis and blOod Pressure Reduction in OLD People","LEOPOLD","Inclusion Criteria:\n\n* 60 to 88 years old patients;\n* Patient with cognitive complaint with MMSE ≥ 20performed within 6 months prior to enrollment (with or without dementia)\n* Patient with a socio-educational level ≥ 3\n* Presence of hyperintensities of moderate to high grade on the last MRI or old scan (grades C and D on the modified Scheltens scale, grades 2\u002F3 Fazekas).\n* Hypertension defined by a Systolic Blood Pressure (SBP) and \u002F or a Diastolic Blood Pressure (DBP) ≥ 140\u002F90 mmHg, treated or not\n* Affiliation to a social security system\n* Informed consent given, signed consent\n\nExclusion Criteria:\n\n* Presence of severe orthostatic hypotension defined as a decrease of 30 mmHg in SBP standing within 3 minutes\n* Contraindication to MRI (presence of ferromagnetic foreign body (especially some intracranial clips, some heart valves, intraocular foreign bodies, metal prosthesis), subject carrying pacemaker, claustrophobic participants)\n* Severe diseases associated with a life expectancy of less than 3 months;\n* Major physical impairments that can interfere with the feasibility of the tests (sight, hearing ...)\n* Presence of another dementia different than Alzheimer's disease vascular dementia or mixed dementia,\n* Persons under guardianship;\n* Secondary hypertension: renovascular hypertension, primary aldosteronism, pheochromocytoma ...;\n* Patient already receiving 4 or more antihypertensive drugs at maximum dosage\n* Patient participating in another clinical research study on drug requiring exclusion period\n* severe renal impairment","ALL","60 Years","88 Years",{"count":97,"type":98},820,"ESTIMATED","INTERVENTIONAL",[101],"PHASE4","The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.",[104],"Cerebrovascular Disorders",[104,106,107,108,109],"Stroke","Antihypertensive Agents","Arterial Pressure","Memory Disorders","2025-09-04",{"date":112,"type":113},"2025-09-05","ACTUAL",{"date":115,"type":113},"2015-09",{"date":117,"type":98},"2028-09-11",{"name":5,"class":6},2]